Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wuxi PharmaTech To Build Largest Preclinical Drug Safety Center In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese pharmaceutical R&D outsourcing services provider WuXi PharmaTech will invest $40 million to build its first good laboratory practices center in Suzhou. The GLP center will be the largest modern drug safety evaluation center in China, the New York Stock Exchange-listed company said Oct. 9
Advertisement

Related Content

China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit
China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit
China’s WuXi To Acquire U.S.-Based AppTec Laboratory Services
China’s WuXi To Acquire U.S.-Based AppTec Laboratory Services
Advertisement
UsernamePublicRestriction

Register

SC065718

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel